Asset Acquisition (Details) - Thymmune Therapeutics, Inc - Subsequent Event $ in Millions |
Jul. 01, 2026
USD ($)
|
|---|---|
| Asset Acquisition [Line Items] | |
| Payments for asset acquisitions | $ 140.0 |
| Asset acquisition contingent consideration | 160.0 |
| First Patient Dosed Milestone | |
| Asset Acquisition [Line Items] | |
| Asset acquisition contingent consideration | 60.0 |
| FDA Biologics License Acceptance Milestone | |
| Asset Acquisition [Line Items] | |
| Asset acquisition contingent consideration | $ 100.0 |